Peptide Reference
AOD-9604
Anti-Obesity Drug-9604
A modified fragment of human growth hormone (amino acids 176-191) designed to stimulate lipolysis without affecting blood sugar or tissue growth. Originally developed as an anti-obesity drug.
Status
clinical
Category
weight loss
Typical cost
$50-100/vial (5mg)
Mechanism
Mimics the fat-burning portion of HGH without the anabolic effects. Stimulates lipolysis and inhibits lipogenesis through beta-3 adrenergic receptor activation. Does not affect IGF-1 levels or glucose metabolism.
Potential benefits
- Targeted fat loss
- No blood sugar effects
- No growth effects
- Improved metabolism
- Cartilage repair
- Joint health
- No IGF-1 elevation
- No organ growth
- Well-tolerated
Reported side effects
- Injection site reactions
- Headache
- Fatigue
- Nausea (rare)
- Limited human data
- Modest effect size
Common dosing references
subcutaneous
300mcg · Daily
4-8 weeks
oral
5-10mg · Daily
4-8 weeks
subcutaneous
300-600mcg · Daily
12-16 weeks
Research notes
AOD-9604 in obesity treatment
2000
Demonstrated significant reduction in body fat with minimal side effects in clinical trials
AOD-9604 and cartilage repair
2015
Showed promising results for cartilage regeneration and joint health
AOD-9604 obesity trial
2007
Modest weight loss in Phase IIb trial, well-tolerated
AOD-9604 safety
2008
No adverse metabolic effects or growth hormone axis disruption
Regulatory and sourcing notes
FDA-approved for lipodystrophy in some contexts. Available by prescription in certain regions. Research status varies.
Prescription in some regions, research chemical in others. Verify local regulations.
Find peptide-aware clinics
Use location pages to compare clinics with peptide therapy signals and verify clinical oversight before treatment.
Related peptides